Latigo Raises $150m To Drive Its First Pain Drug Toward Phase III

Series B Proceeds Will Fund Three NaV1.8 Candidates

 
• By Mandy Jackson
  
Latigo has three NaV1.8 inhibitors and an ASIC inhibitor in development (Shutterstock)

More from Financing

More from Scrip